CytoImmune Therapeutics, Inc. CMO Michael Caligiuiri, MD to Present at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy

CytoImmune Therapeutics, Inc. President William Rosellini to Present at Upcoming Conferences
July 16, 2021
CytoImmune Therapeutics | Wells Fargo Healthcare Conference
September 5, 2021

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today that its Chief Medical Officer, Michael Caligiuri, MD, will be presenting at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy. The event will feature Jeffrey Miller, M.D. (University of Minnesota) and Michael Caligiuri, M.D. (City of Hope National Medical Center) who will discuss CytoImmune’s approach for human natural killer (NK) cell immunotherapy with a heavy focus on programmed death-ligand 1 (PD-L1)+ NK cell for use in treating lung cancer, and fms-like tyrosine kinase 3 (FLT3) CAR NK cell therapy for use in treating Acute Myeloid Leukemia (AML). A live Q&A session will follow the formal presentations.

Register here:

About CytoImmune Therapeutics, Inc.

CytoImmune Therapeutics is a clinical-stage biotechnology company developing a portfolio of natural killer (NK) immunotherapies designed to utilize the power of the patient’s own immune system to eliminate cancer cells. CytoImmune is moving towards filing the Investigational New Drug (IND) applications for novel immunotherapy programs in both solid and hematological malignancies. The company anticipates having programs in human trials in the second half of 2021.


Name: Will Rosellini

SOURCE: CytoImmune Therapeutics